Cytek Biosciences (CTKB) Competitors

$3.96 +0.19 (+5.04%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 0.00 (-0.13%)

As of 04:39 PM Eastern

CTKB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

Should you buy Cytek Biosciences stock or one of its competitors? MarketBeat compares Cytek Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytek Biosciences include Alamar Biosciences (ALMR), Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Cytek Biosciences compare to Alamar Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

69.5% of Cytek Biosciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Alamar Biosciences had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 1 mentions for Cytek Biosciences. Alamar Biosciences' average media sentiment score of 0.65 beat Cytek Biosciences' score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A
Alamar Biosciences	$87.16M	17.50	N/A	N/A	N/A

Cytek Biosciences presently has a consensus target price of $5.69, indicating a potential upside of 43.62%. Alamar Biosciences has a consensus target price of $30.00, indicating a potential upside of 36.36%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Alamar Biosciences beats Cytek Biosciences on 8 of the 12 factors compared between the two stocks.

How does Cytek Biosciences compare to Allient?

Allient (NASDAQ:ALNT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Allient currently has a consensus target price of $72.25, indicating a potential upside of 14.97%. Cytek Biosciences has a consensus target price of $5.69, indicating a potential upside of 43.62%. Given Cytek Biosciences' higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

61.6% of Allient shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 15.0% of Allient shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Allient has a net margin of 4.25% compared to Cytek Biosciences' net margin of -36.25%. Allient's return on equity of 12.47% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Allient has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

In the previous week, Allient had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Allient and 1 mentions for Cytek Biosciences. Allient's average media sentiment score of 0.27 beat Cytek Biosciences' score of 0.00 indicating that Allient is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	1.93	$22.03M	$1.43	43.94
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A

Summary

Allient beats Cytek Biosciences on 12 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Cytek Biosciences has a net margin of -36.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Cytek Biosciences' return on equity of -10.07% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Cytek Biosciences. Eyepoint Pharmaceuticals' average media sentiment score of 0.10 beat Cytek Biosciences' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Eyepoint Pharmaceuticals presently has a consensus price target of $31.80, indicating a potential upside of 148.83%. Cytek Biosciences has a consensus price target of $5.69, indicating a potential upside of 43.62%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytek Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Cytek Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	34.16	-$231.96M	-$3.50	N/A
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A

Summary

Eyepoint Pharmaceuticals beats Cytek Biosciences on 10 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Transcat?

Transcat (NASDAQ:TRNS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Transcat has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

98.3% of Transcat shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.37	$14.52M	$0.85	83.29
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A

Transcat presently has a consensus target price of $105.33, suggesting a potential upside of 48.78%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 43.62%. Given Transcat's stronger consensus rating and higher probable upside, equities research analysts clearly believe Transcat is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Transcat has a net margin of 2.47% compared to Cytek Biosciences' net margin of -36.25%. Transcat's return on equity of 6.15% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

In the previous week, Transcat had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 2 mentions for Transcat and 1 mentions for Cytek Biosciences. Transcat's average media sentiment score of 0.00 equaled Cytek Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Transcat beats Cytek Biosciences on 12 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Frequency Electronics had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Frequency Electronics and 1 mentions for Cytek Biosciences. Frequency Electronics' average media sentiment score of 0.13 beat Cytek Biosciences' score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Frequency Electronics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Frequency Electronics has a net margin of 10.78% compared to Cytek Biosciences' net margin of -36.25%. Frequency Electronics' return on equity of 12.69% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Frequency Electronics presently has a consensus price target of $43.67, suggesting a potential downside of 27.09%. Cytek Biosciences has a consensus price target of $5.69, suggesting a potential upside of 43.62%. Given Cytek Biosciences' higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Frequency Electronics has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	8.44	$23.69M	$0.75	79.85
Cytek Biosciences	$201.49M	2.54	-$66.54M	-$0.57	N/A

Frequency Electronics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Frequency Electronics beats Cytek Biosciences on 12 of the 17 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$511.39M	$3.36B	$6.34B	$12.28B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-6.95	19.02	20.92	25.48
Price / Sales	2.54	278.81	521.15	73.33
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.56	6.90	9.98	7.01
Net Income	-$66.54M	$24.23M	$3.55B	$335.16M
7 Day Performance	17.86%	0.65%	0.40%	-0.30%
1 Month Performance	-14.47%	-0.55%	-0.04%	1.14%
1 Year Performance	59.68%	63.42%	34.95%	34.69%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	1.7277 of 5 stars	$3.96 +5.0%	$5.69 +43.6%	+41.7%	$511.39M	$201.49M	N/A	500
ALMR Alamar Biosciences	4.7999 of 5 stars	$20.51 -1.7%	$30.00 +46.3%	N/A	$1.42B	$87.16M	N/A	222
ALNT Allient	3.8137 of 5 stars	$61.00 +0.1%	$72.25 +18.4%	+99.0%	$1.04B	$560.59M	42.66	2,478
EYPT Eyepoint Pharmaceuticals	2.7145 of 5 stars	$11.82 +1.0%	$31.80 +169.0%	+101.3%	$991.00M	$7.61M	N/A	120
TRNS Transcat	2.4103 of 5 stars	$69.64 -10.4%	$105.33 +51.3%	-28.1%	$649.74M	$278.42M	81.93	1,245	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Allient?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Summary

How does Cytek Biosciences compare to Transcat?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Alamar Biosciences?

Do insiders and institutionals have more ownership in CTKB or ALMR?

Is CTKB or ALMR more profitable?

Does the media prefer CTKB or ALMR?

Which has better earnings and valuation, CTKB or ALMR?

Do analysts recommend CTKB or ALMR?

Summary

How does Cytek Biosciences compare to Allient?

Do analysts rate ALNT or CTKB?

Do institutionals and insiders have more ownership in ALNT or CTKB?

Is ALNT or CTKB more profitable?

Which has more volatility & risk, ALNT or CTKB?

Does the media refer more to ALNT or CTKB?

Which has stronger valuation and earnings, ALNT or CTKB?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Is EYPT or CTKB more profitable?

Does the media prefer EYPT or CTKB?

Which has more volatility & risk, EYPT or CTKB?

Do analysts prefer EYPT or CTKB?

Do institutionals & insiders believe in EYPT or CTKB?

Which has preferable valuation & earnings, EYPT or CTKB?

Summary

How does Cytek Biosciences compare to Transcat?

Which has more risk & volatility, TRNS or CTKB?

Do institutionals and insiders hold more shares of TRNS or CTKB?

Which has preferable earnings & valuation, TRNS or CTKB?

Do analysts recommend TRNS or CTKB?

Is TRNS or CTKB more profitable?

Does the media refer more to TRNS or CTKB?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Does the media refer more to FEIM or CTKB?

Is FEIM or CTKB more profitable?

Do institutionals and insiders hold more shares of FEIM or CTKB?

Do analysts rate FEIM or CTKB?

Which has better earnings & valuation, FEIM or CTKB?

Which has more volatility & risk, FEIM or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools